Clinical Trials Logo

Clinical Trial Summary

A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell non-Hodgkin's lymphoma (B - NHL)


Clinical Trial Description

This study is an open-label, multicenter, Phase 1 dose escalation and Phase 2 dose expansion study of 1A46 in adult patients with advanced relapsed/refractory (r/r) CD20 and/or CD19positive B-cell NHL for whom there is not available effective standard treatment . This study is the FIH study of 1A46 in China. This FIH study will include a dose escalation (Phase 1 part) and a dose expansion in 3 cohorts (Phase 2 part). If specific criteria for efficacy are met in one or more of the Phase 2 cohorts, a statistically validated number of additional patients will be enrolled with the goal of accelerated approval The starting dose for phase I is C1D1 1μg,C1D8 1μg,C1D15 and C2D1 afterwards 1 μg, followed by 10 dose cohorts. Duration of dose limiting toxicity (DLT) observation is 28 days.One cycle is defined as 21 days. Patients will be scheduled to receive weekly injection of 1A46 for the first cycles (3 weeks) and then for the remaining 15 cycles, the study patients will receive a single injection of 1A46 per cycle (every 3 weeks [Q3W]). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05987605
Study type Interventional
Source BioRay Pharmaceutical Co., Ltd.
Contact Zhu Jun, Doctor
Phone +8613910333346
Email zhujun3346@163.com
Status Not yet recruiting
Phase Phase 1
Start date October 1, 2023
Completion date April 30, 2030

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Completed NCT00948961 - A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Terminated NCT02265510 - An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Phase 1/Phase 2
Completed NCT03907969 - A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. Phase 1/Phase 2
Completed NCT03241173 - A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Phase 1/Phase 2
Completed NCT02923349 - A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04025957 - A Study of SHR-1501 in Patients With Advanced Tumors Phase 1
Recruiting NCT05048134 - A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies Phase 1
Completed NCT00651664 - A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies Phase 1
Not yet recruiting NCT06038058 - A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies Phase 1
Completed NCT00611793 - PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies Phase 1
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Terminated NCT02608268 - Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Phase 1/Phase 2
Terminated NCT03277352 - INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Phase 1/Phase 2
Recruiting NCT05577182 - Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies Phase 1
Completed NCT04831996 - To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. Phase 1
Recruiting NCT06468098 - A Study of IBI363 in Subjects With Advanced Malignancies Phase 1
Completed NCT02737501 - ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Phase 3
Completed NCT03158272 - A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread Phase 1